Immunomatics
Raising nowOperatingImmunomatics, Inc.
Biotech · San Marcos, CA
AI to reduce transplant rejection and save lives
This company has an open fundraising round.
Financials
FY2024–FY2025 · from SEC filings · hover any figure for its sourceFigures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited, as the filing’s own report or certification states it. A dashed pill marked * is inferred instead: the SEC minimum for an offering that size, which the issuer may have exceeded. No pill means we couldn’t tell. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Valuation caps on SAFE / convertible note roundsDashed amber bars are a SAFE or convertible note's valuation cap — the most it converts at, not what the company is worth.
Fundraising history
Team
7 people
Specializes in developing AI architectures for complex biomedical data, including spatial imaging and high-dimensional omics, to drive biomarker discovery and clinical risk prediction.
Postdoctoral Research Fellow at the University of Sao Paulo; Visiting Researcher at the MRC Biostatistics Unit, University of Cambridge. Specializes in survival analysis and Bayesian methods. Advises and conducts survival analyses.
Specializes in deep learning for biomedical applications, including computational histopathology software to assess renal glomerular lesions.
Professor and Director of the Immunogenetics and Transplantation Laboratory at UC San Diego. Advises Immunomatics on transplant immunology. Reference to UC San Diego for identification purposes only and does not imply university endorsement or support.
Professor of Biostatistics at the Federal University of Sao Carlos (UFSCar). Specializes in survival analysis, cure fraction models, and frailty modeling. Advises on survival analysis methods.
Names and titles as disclosed on WeFunder, SEC Form C. Bios and photos come from the platform campaign page and may be out of date.
Reg CF annual-report compliance
never closed a Reg CF raise
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
- Form CAug 12, 20260002148987-26-000001EDGAR
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.